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ABSTRACT
We hypothesize that exogenous administration of anti-inflammatory cytokine interleukin (IL)-10 would affect the secretion
of pro-inflammatory cytokines such as IL-1β, IL-6, or tumor necrosis factor (TNF)–α using lipopolysaccharide (LPS)-stimulated macrophages exuded from the peritoneal cavity of female BALB/c mice. The LPS-stimulated macrophages were incubated
for 48 hr to investigate the secretions of pro- and anti-inflammatory cytokine. The results indicated that the secretion levels of
IL-1β, IL-6, IL-10, and TNF–α by LPS-stimulated macrophages elevated in a time dependent manner during 48-hr incubation
period. The amount of cytokines secretion by LPS-stimulated macrophages varied: IL-6 > TNF-α > IL-10 > IL-1β. However,
the secretion of IL-10 started to decrease at 18 hr of incubation. Therefore, the macrophage cultures were extra-administrated
with various concentrations (0, 75, 150, and 225 pg/mL) of exogenous IL-10 after 18-hr incubation in order to evaluate the effect
of exogenous IL-10 administration on inflammation. IL-10, IL-1β, IL-6, and TNF–α in LPS-stimulated macrophage cultures
before and after exogenous IL-10 administration were determined by ELISA. The results demonstrated that exogenous IL-10
administration inhibited IL-1β (21.3-38.6%) and TNF–α (44.7-66.8%) secretion. However, the administration did not inhibit
IL-6 secretion. Low dose (75 pg/mL) of exogenous IL-10 exerted maximal effects. IL-10 levels in LPS-stimulated macrophage
cultures after exogenous IL-10 administration increased from 18.4% to 35.5%. Furthermore, only low dose of exogenous IL-10
administration increased endogenous IL-10 secretion (by 10.4%), while higher doses of exogenous IL-10 inhibited endogenous
IL-10 production (from 31.7% to 41.9%). The results suggest that low dose administration of exogenous IL-10 might exhibit antiinflammatory effects via inhibiting TNF-α and IL-1β, but not IL-6, secretion and increasing endogenous IL-10 production by
LPS-stimulated peritoneal macrophages.
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INTRODUCTION
Interleukin (IL)-10 is regarded as a pleiotropic
cytokine. Five novel cytokines, IL-19, IL-20, IL-22,
IL-24, and IL-25, with limited primary sequence identity
and probable structural homology to IL-10 have been
identified recently (1). IL-10 is an 18.7 kD polypeptide
produced by a variety of human immune cells, including T helper type 1 (Th1), and Th2 cells, B cells, monocytes, macrophages, dendritic cells (DC), mast cells, and
eosinophils (2) . Much evidence has accumulated over
past few years implicating the anti-inflammatory role of
IL-10. Currently, data suggest that IL-10 inhibits Th1and Th2-type immune responses. However, IL-10 favors
humoral immunity and cytotoxic T lymphocyte function by acting directly on relevant cells and influencing
immunomodulatory cells such as T regulatory, DC, and
natural killer cells (3). Therefore, IL-10 is involved in
the inflammatory and immune reactions, and has potent
* Author for correspondence. Tel: +886-4-22851857;
Fax: +886-4-22851857; E-mail: jinlin@nchu.edu.tw

anti-inf lammatory and immunosuppressive activities
on myeloid cells (4). IL-10 regulates potential molecular pathways via the mitogen-activated protein kinase
(MAPK) components to mediate the inf lammation and
cell death(5). Thus, IL-10 is postulated to play a crucial
role in acute and chronic inf lammatory diseases, such
as allergic diseases (6), experimental pancreatitis (7), and
ozone-induced lung injury (8). The functions of IL-10 and
its applications on the immunomodulation have attracted
great attention.
Inf lammation can be def ined as the sequential
release of mediators such as pro-inflammatory cytokines,
including IL-1, tumor necrosis factor (TNF), interferon
(IFN)-γ, IL-12, IL-18, and the granulocyte-macrophage
colony-stimulating factor, and is settled by anti-inflammatory cytokines such as IL-4, IL-10, IL-13, IFN-α, and
the transforming growth factor (TGF)-β (9). Chronic or
non-necessary inf lammation may cause tissue damage
such as atherosclerotic intimas in human coronary arteries, systemic lupus erythematosus, and autoimmune
rheumatic diseases (10-11). The mechanisms by which the
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inf lammatory responses, such as the pro-inf lammatory
cytokine secretion and the inhibition by anti-inflammatory cytokine such as IL-10, is resolved might provide new
targets in the treatment of acute or chronic inflammation
in vivo.
IL-10 is a well known anti-inf lammatory cytokine
and plays an important role in suppressing the inf lammatory response in many in vitro or in vivo experimental models. It has been reported that IL-10 inhibits the
release of pro-inflammatory cytokines IL-6 and TNF-α
by human monocyte/macrophage in response to polymethylmethacrylate (PMMA, spherical 1-10 μm) particle
challenge in vitro (12) . IL-10 potently abrogates the
proliferative response of human vascular smooth muscle
to atherogenic mitogens such as TNF-α and basic fibroblast growth factor (13). Li et al.(14) hypothesized that
enhancing anti-inf lammatory cytokine IL-10 may be a
promising approach for acute coronary disease therapy.
Monocytes and macrophages can produce a large
repertoire of cytokines and participate in the pathogenesis of granulomatous diseases (15), hepatitis (16) and
damage neuro-inf lammatory insults such as hypoxiaischemia (17). In some cases, IL-10 may provide protective effects. However, the timing of IL-10 production/
administration and pro-inflammatory cytokines secretion
by activated macrophages remain to be further investigated. To elucidate the pharmacological effects of IL-10
on pro-inf lammatory cytokine action and production,
lipopolysaccharide (LPS)-stimulated peritoneal macrophages from BALB/c mice were cultured in vitro in this
study. The LPS, a component of the gram negative cell
wall, was used to stimulate peritoneal macrophages and
to induce the production of inflammatory cytokines via
the stimulation of Toll-like receptors in macrophages.
Here, we report the time dependent production of proand anti-inflammatory cytokines upon exogenous IL-10
administration and endogenous IL-10 production by
LPS-stimulated peritoneal macrophages.

MATERIALS AND METHODS
I. Animals
The female BALB/cByJ Narl mice (6 weeks old)
were obtained from the National Laboratory Animal
Center, National Applied Research Laboratories, National Science Council in Taipei, Taiwan, ROC and maintained in the Department of Food Science and Biotechnology at National Chung Hsing University, College of
Agriculture and Natural Resources in Taichung, Taiwan,
ROC. The mice were housed and kept on a chow diet
(laboratory standard diet). The animal room was kept on
a 12-hr-light and 12-hr-dark cycle. Constant temperature
(25 ± 2°C) and relative humidity (50-60%) were maintained. After acclimation for 4 weeks, the mice were
sacrificed to obtain peritoneal macrophages.

II. Peritoneal Macrophages Isolation and Cultures
Brief ly, the adult female BALB/c mice were anesthetized with diethyl ether, exsanguinated using a retroorbital venous plexus puncture and immediately euthanized by CO2 inhalation. Peritoneal cells were prepared
by lavaging the peritoneal cavity twice with 5 mL of
sterile Hank’s balanced salts solution through peritoneum. The peritoneal lavage f luid was centrifuged at
200 ×g for 10 min at 4°C. The cell pellets were collected
and resuspended in TCM medium (TCM, a multipurpose
serum replacement from CELOX Laboratories). The
peritoneal adherent cells (mostly macrophages) from
each animal were adjusted to 2 × 106 cells/ mL in TCM
medium by hemocytometry and trypan blue dye exclusion method. Peritoneal adherent cells (0.50 mL/well)
in the presence of stimulus, LPS (Sigma L-2654, 0.5
mL/well, 10 μg/mL) were plated in 48-well plates. The
plates were incubated at 37°C in a humidified incubator
with 5% CO2 and 95% air for up to 48 hr. The culture
supernatants were collected respectively at 0, 6, 12, 18,
24, 48 hr after incubation. The plates were centrifuged
at 200 ×g for 10 min and the supernatants were collected
and stored at -80°C for later cytokine assays.
III. IL-10 Administration
To measure the effects of exogenous IL-10 administration on the secretion of pro-inf lammatory cytokines and endogenous anti-inflammatory cytokines, the
LPS-stimulated peritoneal macrophage cultures were
individually administrated with various amounts (final
concentrations 0, 75, 150, and 225 pg/mL) of IL-10
(mouse IL-10, R&D Systems DY417) after 18-hr incubation. The plates were incubated at 37°C and the culture
supernatants were collected as described above, at the
incubation time of 0, 6, 12, 18, 24 and 48 hr, respectively,
before and after exogenous IL-10 administration.
IV. Determination of Cytokines Secretion by ELISA
Cytokine (IL-1β, IL-6, IL-10, and TNF-α) levels in
LPS-stimulated peritoneal macrophage cultures were
determined using sandwich ELISA kits, respectively,
according to the manufacturer’s instructions [mouse
DuoSet ELISA Development system (R&D Systems)].
The sensitivity of these cytokine assays was about 15.6
pg/mL.
V. Statistical Analysis
Data were expressed as mean ± S.E. and analyzed
statistically using Dunnett’s test of parametric type.
Differences between the exogenous IL-10 administration
groups and control were considered statistically significant if P < 0.05.
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II. Effects of IL-10 Administration on the IL-1β Secretion
To determine if IL-10 demonstrates its anti-inflammatory effect via inhibiting IL-1β secretion in vitro,
the exogenous IL-10 was added to the LPS-stimulated
macrophages culture at the incubation time of 18 hr. The
results showed that exogenous IL-10 in concentrations of
75 pg/mL (low dose), 150 pg/mL (medium dose), and 225
pg/mL (high dose) respectively inhibited the secretions
of pro-inflammatory cytokine IL-1β (Figure 2). Although
the exogenous IL-10 inhibited IL-1β secretion, the inhibitory manner was not dose-dependent. The low administration dose (75 pg/mL) had a maximum inhibitory effect
and decreased IL-1β secretion by 38.6% (from 181 ± 70
pg/mL to 111 ± 65 pg/mL) compared to the control (0 pg/
mL IL-10 added) after 30 hr of exogenous IL-10 administration. The medium and high administration doses
(150 and 225 pg/mL) decreased IL-1β secretion by 32.6%
(from 181 ± 70 to 149 ± 67 pg/mL) and 21.3% (from 181
± 70 to 143 ± 72 pg/mL), respectively.
III. Effects of IL-10 Administration on the IL-6 Secretion
The effects of exogenous IL-10 administration on
IL-6 secretion in LPS-stimulated macrophages are shown
in Figure 3. The results revealed that low, medium, and
high doses of exogenous IL-10 slightly, but not significantly (P > 0.05) increased IL-6 secretion by 10.3% (from

IV. Effects of IL-10 Administration on the TNF-α Secretion
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To investigate the time cou rse of the cy tokine
secretion in LPS-stimulated peritoneal macrophages,
both anti-inf lammatory (IL-10) and pro-inf lammatory
(IL-1β, IL-6, and TNF–α) cytokines were determined.
The results showed that all the levels of IL-10, IL-1β,
IL-6, and TNF–α secretion in the macrophages culture
increased, although slightly fluctuated, in a time-dependent manner during the 48-hr incubation period (Figure
1). We found that the secretion amount varied: IL-6 >
TNF-α > IL-10 > IL-1β; the secretion amounts of IL-6,
TNF-α, IL-10, and IL-1β at 48-hr incubation time were
7.170 ± 0.248, 2.072 ± 0.801, 0.299 ± 0.085, and 0.181 ±
0.070 ng/mL respectively.
A maximal cytokine secretion rate, except for that
of IL-10, in LPS-stimulated macrophages was found
during the first 12-hr incubation. Although a steady
cytokine secretion rate maintained after 24-hr incubation, the secretion amount of IL-10 decreased at the time
of 18-hr incubation. To evaluate the effect of exogenous
IL-10 administration on inflammation, 18 hr was chosen
to be the time to administrate exogenous IL-10 to avoid
the inhibition of cytokine synthesis at the beginning of
endotoxin (LPS) treatment.
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mL to 8.39 ± 2.50 ng/mL), respectively, compared to the
control after 30 hr of exogenous IL-10 administration.
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Figure 1. The time courses of IL-10, IL-1β, IL-6 and TNF-α
production using LPS-stimulated peritoneal macrophage cultures
from female BALB/c mice. The secretions from the cell cultures
were determined after LPS (10 μg/mL) addition for 0, 6, 12, 18, 24
and 48 hr, respectively. Data are represented as mean ± SE (n = 3).
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Figure 2. Exogenous IL-10 administration effects on the IL-1β
secretion using LPS-stimulated peritoneal macrophage cultures
from female BALB/c mice. The secretions of IL-1β from the cell
cultures were determined at the indicated incubation time 0, 6, 12,
18, 24 and 48 hr, respectively. The exogenous IL-10 was added to
the cell cultures after 18-hr incubation. Data are represented as
mean ± SE (n = 3).
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respectively, inhibited the secretions of pro-inf lammatory cytokine TNF-α in LPS-stimulated macrophages
(Figure 4). Although the exogenous IL-10 administra-

Effects of superadditional IL-10 on IL-6 levels
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tion inhibited TNF-α secretion, the inhibitory manner
was not dose-dependent either. The low dose of exogenous IL-10 administration had a maximal inhibitory
effect and decreased TNF-α secretion by 66.8% (from
2.07 ± 0.80 ng/mL to 0.77 ± 0.47 ng/mL) compared to the
control after 30 hr of exogenous IL-10 administration.
The medium and high administration doses decreased
TNF-α secretion by 44.7% (from 2.07 ± 0.80 ng/mL to
1.15 ± 0.50 ng/mL) and 51.8% (from 2.07 ± 0.80 ng/mL
to 1.00 ± 0.50 ng/mL) during the same time course.
V. Effects of IL-10 Administration on the IL-10 Secretion
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Figure 3. Effects of exogenous IL-10 administration effects on IL-6
secretion using LPS-stimulated peritoneal macrophage cultures
from female BALB/c mice. The secretions of IL-6 from the cell
cultures were determined at the indicated incubation time 0, 6, 12,
18, 24 and 48 hr, respectively. The exogenous IL-10 was added to
the cell cultures after 18 hr incubation. Data are represented as
mean ± SE (n = 3).

The effects of exogenous IL-10 administ ration
on IL-10 secretion by LPS-stimulated macrophages
are shown in Figure 5. The results revealed that low,
medium, and high doses of exogenous IL-10 administration seemed to increase IL-10 concentrations in the
LPS-stimulated macrophages by 35.5% (from 299 ± 86
pg/mL to 405 ± 66 pg/mL), 18.4% (from 299 ± 86 pg/mL
to 354 ± 56 pg/mL), and 33.2% (from 299 ± 86 pg/mL to
399 ± 32 pg/mL), respectively, compared to control after
30 hr of exogenous IL-10 administration. To determine
the net endogenous IL-10 secretion by LPS-stimulated
macrophages, the concentrations of exogenous IL-10
added to the medium at 18 hr were individually subtracted from those of LPS-stimulated macrophages after 30
hr of exogenous IL-10 administration. Net changes of
endogenous IL-10 secretions by LPS-stimulated macrophages upon extra-administration of low, medium, and
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Figure 4. Exogenous IL-10 administration effects on the TNF-α
secretion using LPS-stimulated peritoneal macrophage cultures
from female BALB/c mice. The secretions of TNF-α from the cell
cultures were determined at the indicated incubation time 0, 6, 12,
18, 24 and 48 hr, respectively. The exogenous IL-10 was added to
the cell cultures after 18 hr incubation. Data are represented as
mean ± SE (n = 3).
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Figure 5. Exogenous IL-10 administration effects on the total IL-10
levels using LPS-stimulated peritoneal macrophage cultures from
female BALB/c mice. The secretions of IL-10 from the cell cultures
were determined at the indicated incubation time 0, 6, 12, 18, 24
and 48 hr, respectively. The exogenous IL-10 was added to the cell
cultures after 18 hr incubation. Data are represented as mean ± SE
(n = 3).
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high doses of exogenous IL-10 were from 299 to 330 pg/
mL (increase by 10.4%), from 299 to 204 pg/mL (decrease
by 31.7%), and from 299 to 174 pg/mL (decrease by
41.9%), respectively.

DISCUSSION
Monocytes/macrophages play an impor tant role
in the persistence of chronic inf lammation and local
t issue dest r uct ion i n d iseases such as rheu matoid
arthritis, atherosclerosis, brain, and bronchoalveolar
inf lammation (18-20). However, the time course of cytokine secretion and anti-inf lammator y regulation by
inflamed macrophages itself is still not fully understood.
In this study, we established an in vitro model using
LPS-stimulated primary peritoneal macrophages from
female BALB/c mice to evaluate the interaction between
pro-inf lammatory and anti-inf lammatory cytokines.
We found that LPS, an endotoxin, stimulated peritoneal
macrophges to produce both pro-inf lammatory cytokines (IL-1β, IL-6, and TNF–α) and anti-inf lammatory
cytokine (IL-10) in vitro (Figure 1). However, exogenous IL-10 administration significantly affected the
cytokines secretion and may relieve the inf lammation
status of LPS-stimulated peritoneal macrophages via
decreasing the secretion of pro-inflammatory cytokines,
such as IL-1β and TNF-α (Figures 2 and 4), and increasing the secretion of anti-inf lammatory cytokine, such
as IL-10 (Figure 5). MacKenzie et al.(21) reported that
LPS stimulates monocyte/macrophage cells in primary
culture from trout Oncorhynchus mykiss and activate the
LPS-dependent TNF-α expression(21). Peritoneal macrophages from mice treated with LPS produce IL-10 and
the IL-10 production is promoted by the serine/threonine
kinase Akt pathway (22). In this study, total IL-10 level
(including exogenous and endogenous IL-10) was significantly (P < 0.05) negatively correlated, respectively, with
IL-1β and TNF-α. levels in the LPS-stimulated macrophages culture. This study provides clues of the secretion time course and interaction between pro- and antiinflammatory cytokines in LPS-stimulated macrophages
in nature.
Inf lammation progress consists of complicated
release of mediators and recruiting circulating leukocytes to the inflammatory site. However, in some cases,
the inflammatory response is alleviated by the release of
endogenous anti-inf lammatory mediators and the accumulation of intracellular negative regulatory factors (9).
In this study, although pro-inf lammator y cytokines
IL-1β, IL-6, and TNF–α were produced by LPS-stimulated peritoneal macrophages, an endogenous anti-inflammatory cytokine IL-10 might be produced by the same
cells (Figure 1). Sumiyoshi et al.(10) reported that the
IL-10 expression is positively correlated with oxidized
low density lipoprotein deposition in the atherosclerotic
intimas of human coronary arteries. The results suggest

that the inf lammatory balance modulated by pro- and
anti-inflammatory cytokines produced by LPS-stimulated macrophages does exist.
An endogenous anti-inf lammatory cytokine IL-10
might modulate the inf lammatory responses via regulating the M A PK components which have emerged
as potential signaling cascades in the regulation of a
plethora of cell functions, including inf lammation and
cell death (5) . We hypothesized that exogenous IL-10
administration might enhance the anti-inf lammatory
effects of LPS-stimulated macrophages. The resolution of the effect of exogenous IL-10 on LPS-stimulated
macrophages might establish a basis for the current
therapeutical intervention concepts of IL-10 for different inf lammatory diseases. In this study, the results
revealed t hat t he exogenou s I L -10 a d m i n ist r at ion
significantly decreased the pro-inf lammatory cytokine
secretions, IL-1β and TNF-α, and increased the total
IL-10, including exogenous and endogenous, level in the
culture. The results suggest that exogenous IL-10 can
inhibit IL-1β and TNF-α secretion by inf lamed macrophages and might alleviate the inf lammation status in
vitro or in vivo. However, the effects of exogenous IL-10
administration on IL-1β, TNF-α, and IL-10 secretion
did not demonstrate in a dose dependent manner. The
low dose of exogenous IL-10 administration seemed to
have a maximal effect. To further clarify the puzzle, the
endogenous IL-10 secretion by LPS-stimulated macrophages after extra-administrated with exogenous IL-10
were determined. The changes of endogenous IL-10
production from LPS-stimulated macrophages after
extra-administrated with low, medium, and high doses
of exogenous IL-10 were +10.4%, -31.7%, and -41.9%
(Figure 5). Low dose of exogenous IL-10 administration slightly induced the endogenous IL-10 secretion.
However, higher doses of exogenous IL-10 inhibited the
endogenous IL-10 secretion. The results suggest that the
biological concentration of endogenous IL-10 is constitutively regulated. However, this study was not aimed to
elucidate the detailed mechanism by which the stability
or half-life of exogenous IL-10 was mentioned in the cell
culture model. Determination of the endogenous IL-10
level by directly subtracting exogenous IL-10 levels
added to the medium at 18 hr from total IL-10 levels
may cause a bias on endogenous IL-10 levels. Certain
cells modulate IL-10 secretion via negative-feedback or
positive-feedback regulation (9). The magnitude of the
immune cell response generally depends on the dose
of stimulant administered. However, extremely low or
high stimulant doses may induce specific irresponsive
states (acquired low-zone or high-zone tolerance)(23). In
this study, our results suggest that low dose (75 pg/mL)
administration of exogenous IL-10 has maximal antiinflammatory effects via decreasing the pro-inflammatory cytokines production, such as IL-1β and TNF-α, and
increasing the endogenous anti-inf lammatory cytokine,
such as IL-10, in this in vitro model. However, the prac-
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tical uses of exogenous IL-10 in the immunotherapy
against inflammation and the regulation between endogenous and exogenous IL-10 levels remain to be explored.
IL-6 is known to be a multifunctional cytokine that
modulates the immune response, hematopoiesis, acute
phase response and inf lammation (24). Deregulation of
IL-6 production is beneficial in the inflammation pathology or several disease processes, such as prostate cancer
progression(25). ST2, a member of IL-1 receptor family
expressed in Th2 cells, negatively regulates LPS-induced
IL-6 production via the inhibition of IκB degradation in
THP-1 cells (26). Trindade et al.(12) reported that IL-10
inhibits the release of the pro-inf lammatory cytokines
IL-6 and TNF-α in human monocyte/macrophage in
response to PMM A par ticle challenge in vitro. In
this study, LPS induced IL-6 production of peritoneal
macrophages. However, in contrary to our hypothesis,
exogenous IL-10 administration could not inhibit IL-6
secretion by LPS-stimulated macrophages. IL-6 is an
acute phase pro-inflammatory cytokine and the secretion
amount of IL-6 was much higher than that of IL-10 (about
20 folds) (Figure 1). Administration time point and
concentrations of exogenous IL-10 intervention might
cause a contray result of IL-6 secretion. The reason
remains to be further elucidated.
In conclusion, this study demonstrated that exogenous IL-10 administration significantly inhibited IL-1β
and T NF– α secretion but increased IL-10 levels in
LPS-stimulated peritoneal macrophage cultures. The
results suggest that low dose of exogenous IL-10 administration might exhibit anti-inf lammatory effects via
inhibiting TNF-α and IL-1β secretion and increasing
endogenous IL-10 secretion by LPS-stimulated peritoneal macrophages. These results will be important and
useful in the future exploitation of cytokine therapy and
anti-inflammation evaluation.
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